| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6191403 | European Journal of Surgical Oncology (EJSO) | 2015 | 7 Pages |
Abstract
The addition of bevacizumab to combination chemotherapy showed more necrosis but less fibrosis of metastases compared to cetuximab and a trend towards higher histological and radiological response and longer RFS. Further investigations of biological tumor characteristics are required to individualize treatment combinations.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Stremitzer, J. Stift, J. Singh, P. Starlinger, B. Gruenberger, D. Tamandl, T. Gruenberger,